The drug giants won European Union regulatory approval for a complicated series of deals worth more than $20 billion that will focus Novartis’ scope and turn Glaxo into a vaccines-and-consumer-drug powerhouse.
WSJ.com: What's News US, Wall Street Journal
Wed, 01/28/2015 - 10:33am
The drug giants won European Union regulatory approval for a complicated series of deals worth more than $20 billion that will focus Novartis’ scope and turn Glaxo into a vaccines-and-consumer-drug powerhouse.